Literature DB >> 2022706

Peripheral glucose metabolism in acromegaly.

M C Foss1, M J Saad, G M Paccola, F J Paula, C E Piccinato, A C Moreira.   

Abstract

The present study was designed to determine the effect of chronic GH excess on forearm muscle glucose uptake and oxidation during the postabsorptive state and after an oral glucose challenge. Nine normal subjects and 10 nondiabetic acromegalic patients (5 of them with normal glucose tolerance) were studied after an overnight fast (12-14 h) and for 3 h after the ingestion of 75 g glucose. Peripheral glucose metabolism was analyzed by the forearm technique to estimate muscle exchange of substrate combined with indirect calorimetry. Decreased forearm glucose uptake was observed in the acromegalic patients compared to that in the normal subjects (380 +/- 84 vs. 709 +/- 56 mumol/100 mL forearm.3 h) with diminished nonoxidative glucose metabolism (262 +/- 81 vs. 572 +/- 53 mumol/100 mL forearm.3 h). The acromegalics with normal glucose tolerance also showed decreased forearm glucose uptake and nonoxidative glucose metabolism compared to normal subjects (271 +/- 124 vs. 709 +/- 56 and 133 +/- 110 vs. 572 +/- 53 mumol/100 mL forearm.3 h, respectively). Muscle glucose oxidation did not differ significantly in normal subjects, the entire group of acromegalic patients, and the acromegalics with normal glucose tolerance (137 +/- 18 vs. 118 +/- 22 vs. 138 +/- 34 mumol/100 mL forearm.3 h, respectively). Serum FFA levels and lipid oxidation rates were similar in the normal subjects and the acromegalic patients, and declined in a similar fashion after glucose ingestion. Insulin levels were significantly higher in acromegalic patients than in normal subjects before and after glucose loading. In conclusion, this study showed that the insulin resistance occurring in the presence of chronic GH excess is accompanied by impaired muscle glucose uptake and nonoxidative glucose metabolism, which are early derangements because they are also observed in acromegalic patients with normal glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022706     DOI: 10.1210/jcem-72-5-1048

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Therapy of diabetes and dyslipidemia in acromegaly.

Authors:  G Tamburrano; C Durante; R Baldelli
Journal:  Pituitary       Date:  2002-01       Impact factor: 4.107

Review 2.  Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models.

Authors:  Darlene E Berryman; Jens Sandahl Christiansen; Gudmundur Johannsson; Michael O Thorner; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2008-08-16       Impact factor: 2.372

3.  Increased fibrosis: A novel means by which GH influences white adipose tissue function.

Authors:  Lara A Householder; Ross Comisford; Silvana Duran-Ortiz; Kevin Lee; Katie Troike; Cody Wilson; Adam Jara; Mitchell Harberson; Edward O List; John J Kopchick; Darlene E Berryman
Journal:  Growth Horm IGF Res       Date:  2017-12-20       Impact factor: 2.372

4.  Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.

Authors:  Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer
Journal:  JCI Insight       Date:  2020-03-12

5.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors:  Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

6.  Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy.

Authors:  R Baldelli; C Durante; E D'Amico; F Diacono; G Tamburrano; F F Casanueva
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

Review 7.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors:  Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues.

Authors:  C L Ronchi; E Orsi; C Giavoli; V Cappiello; P Epaminonda; P Beck-Peccoz; M Arosio
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.